SJ000291942
Based on 3 publication(s) in Google Scholar
SJ000291942 is an activator of the canonical bone morphogenetic proteins (BMP) signaling pathway. BMPs are members of the transforming growth factor beta (TGFβ) family of secreted signaling molecules.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.66%
- CAS 番号: 425613-09-8
- 分子式: C16H15FN2O4
- 分子量:318.30
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
MedChemExpress(MCE)の使用を引用している文献 SJ000291942
More
生物活性
BMP[1]
Embryos treated with SJ000291942 display the most severe ventralization and SJ000291942 is also the most potent. SJ000291942 also causes more mortality, and at lower doses than controls and the other two compounds. This demonstrates our compounds cause ventralization of embryos consistent with increased BMP signaling activity. SJ000291942 causes an increase in bmp2b and szl expression. Zebrafish assays suggest that SJ000291942 activates the canonical BMP signaling pathway. To extend these observations, immunoblotting of protein lysates from C33A-2D2 cells stimulated with SJ000291942 at different times is performed. SJ000291942 activates phosphorylation of SMAD1/5/8 in serum-free medium. Like in zebrafish embryos, SJ000291942 is most active. SJ000291942 induces p-SMAD1/5/8 maximally at 1hr of treatment. Immunoblotting analysis of lysates from C33A-2D2 treated with SJ000291942 reveals clear induction of the phosphorylated Extracellular Signal-regulated protein Kinase, ERK1/2 (P-ERK1/2) by SJ000291942. The highest dose (100 and 300ng) BMP4 treatments generate a gene expression signature most similar to osteoblast expression. Low dose (10ng) BMP4 treatment aligns closely with 25μM compound 3 treatment and with 25μM SJ000291942[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
CAS 番号 425613-09-8
-
性状 Solid
-
分子量 318.30
-
分子式 C16H15FN2O4
-
Color White to off-white
-
SMILES
O=C(NC1=CC=C(F)C([N+]([O-])=O)=C1)COC2=CC=C(CC)C=C2
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Prostate
Upregulated bone morphogenetic protein 5 enhances proliferation and epithelial-mesenchymal transition process in benign prostatic hyperplasia via BMP/Smad signaling pathway. [Abstract]2021 Dec;81(16):1435-1449. PMID: 34553788 -
Biochim Biophys Acta Gen Subj
Expression of GALNT8 and O-glycosylation of BMP receptor 1A suppress breast cancer cell proliferation by upregulating ERα levels. [Abstract]2022 Jan;1866(1):130046. PMID: 34743989 -
溶剤 & 溶解度
DMSO : ≥ 150 mg/mL (471.25 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.85 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (272 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.1417 mL | 15.7085 mL | 31.4169 mL | 78.5423 mL |
| 5 mM | 0.6283 mL | 3.1417 mL | 6.2834 mL | 15.7085 mL | |
| 10 mM | 0.3142 mL | 1.5708 mL | 3.1417 mL | 7.8542 mL | |
| 15 mM | 0.2094 mL | 1.0472 mL | 2.0945 mL | 5.2362 mL | |
| 20 mM | 0.1571 mL | 0.7854 mL | 1.5708 mL | 3.9271 mL | |
| 25 mM | 0.1257 mL | 0.6283 mL | 1.2567 mL | 3.1417 mL | |
| 30 mM | 0.1047 mL | 0.5236 mL | 1.0472 mL | 2.6181 mL | |
| 40 mM | 0.0785 mL | 0.3927 mL | 0.7854 mL | 1.9636 mL | |
| 50 mM | 0.0628 mL | 0.3142 mL | 0.6283 mL | 1.5708 mL | |
| 60 mM | 0.0524 mL | 0.2618 mL | 0.5236 mL | 1.3090 mL | |
| 80 mM | 0.0393 mL | 0.1964 mL | 0.3927 mL | 0.9818 mL | |
| 100 mM | 0.0314 mL | 0.1571 mL | 0.3142 mL | 0.7854 mL |